KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $10.3 million.

  • Travere Therapeutics' Other Non-Current Assets fell 4010.75% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 4010.75%. This contributed to the annual value of $18.2 million for FY2024, which is 7035.93% up from last year.
  • Latest data reveals that Travere Therapeutics reported Other Non-Current Assets of $10.3 million as of Q3 2025, which was down 4010.75% from $19.6 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Other Non-Current Assets ranged from a high of $48.3 million in Q4 2022 and a low of $10.3 million during Q3 2025
  • Its 5-year average for Other Non-Current Assets is $19.1 million, with a median of $16.9 million in 2024.
  • In the last 5 years, Travere Therapeutics' Other Non-Current Assets skyrocketed by 41491.99% in 2021 and then tumbled by 7794.67% in 2023.
  • Over the past 5 years, Travere Therapeutics' Other Non-Current Assets (Quarter) stood at $11.1 million in 2021, then soared by 336.73% to $48.3 million in 2022, then tumbled by 77.95% to $10.7 million in 2023, then soared by 70.36% to $18.2 million in 2024, then plummeted by 43.55% to $10.3 million in 2025.
  • Its last three reported values are $10.3 million in Q3 2025, $19.6 million for Q2 2025, and $18.7 million during Q1 2025.